Blog
RSS FeedPosted by Michael Wonder on 04 Jan 2021
Ibrutinib with rituximab in previously untreated chronic lymphocytic leukaemia: indication of added benefit over FCR
4 January 2020 - The new drug combination prolongs overall survival in patients in good general health. No study data are ...
Posted by Michael Wonder on 17 Sep 2020
The best possible security of supply for cancer therapy with CAR-T cells
17 September 2020 - Medical facilities that treat patients with novel cell therapies (CAR-T cells) must meet newly defined quality requirements. ...
Posted by Michael Wonder on 02 Sep 2020
Talazoparib in breast cancer: hint of considerable added benefit
1 September 2020 - Advantages in health related quality of life, symptoms and side effects outweigh disadvantages. ...
Posted by Michael Wonder on 17 Aug 2020
Castration-resistant prostate cancer with a high risk of metastasis: enzalutamide has an additional benefit
17 August 2020 - New data from the PROSPER study shows benefit in overall survival. ...
Posted by Michael Wonder on 06 Aug 2020
Darolutamide in prostate cancer: indication of considerable added benefit
3 August 2020 - Advantages in overall survival, symptoms and health-related quality of life. ...
Posted by Michael Wonder on 17 Jul 2020
Determination of the target population in early benefit assessments in Germany: challenges for non-small-cell lung cancer
17 July 2020 - Dossiers submitted for early benefit assessments in Germany also provide information on the precise determination of the ...
Posted by Michael Wonder on 11 Jul 2020
How can cancer drug prices better match their benefits? Germany offers a cost-saving model
10 July 2020 - After Germany revamped its approach to purchasing medicines a decade ago, the prices negotiated by the ...
Posted by Michael Wonder on 07 Jul 2020
Lessons from the impact of price regulation on the pricing of anti-cancer drugs in Germany
7 July 2020 - Worldwide spending on prescription drugs has increased dramatically in recent years. Although this increase has been particularly ...
Posted by Michael Wonder on 02 Jun 2020
Ribociclib succinate in breast cancer: added benefit for certain post-menopausal women
2 June 2020 - Re-valuations after the expiry of the time limit new data cuts confirm advantages and disadvantages ...
Posted by Michael Wonder on 16 Jan 2020
Larotrectinib in tumours with NTRK gene fusion: data are not yet sufficient for derivation of an added benefit
15 January 2020 - First assessment of a histology-independent drug/studies without control arms. ...
Posted by Michael Wonder on 05 Aug 2019
Dacomitinib in advanced lung cancer: variety of disadvantages lifts survival advantage
1 August 2019 - Prolonged survival is sometimes accompanied by severe side effects, symptom and quality of life deterioration ...
Posted by Michael Wonder on 10 Jul 2019
Biomarker-based cancer diagnostics: German pricing regulator sets high validation and reimbursement standards for novel diagnostic methods
10 July 2019 - On 20 June 2019, for the first time, the German Federal Joint Committee (G-BA), made the resolution ...
Posted by Michael Wonder on 15 May 2019
Nivolumab and ipilimumab: drug combination has added benefit in advanced renal cell carcinoma
15 May 2019 - There are no serious disadvantages in terms of overall survival. ...
Posted by Michael Wonder on 16 Apr 2019
Ribociclib in advanced breast cancer: survival benefits, but also severe side effects
15 April 2019 - In the overall view, an added benefit is not proven. ...
Posted by Michael Wonder on 15 Jan 2019
Progressive squamous cell carcinoma of the head and neck: pembrolizumab prolongs survival
15 January 2019 - Only a few study participants were treated in compliance with the approval, therefore the extent of ...